Background: Before pandemic (H1N1) 2009, less than 10% of serum samples collected from all age groups in the Lower Mainland of British Columbia, Canada, showed seroprotection against the pandemic (H1N1) 2009 virus, except those from very elderly people. We reassessed this profile of seroprotection by age in the same region six months after the fall 2009 pandemic and vaccination campaign.
I n a previous age-based survey of about 1000 anonymized serum samples collected before substantial pandemic (H1N1) 2009 activity in the Lower Mainland of the province of British Columbia, Canada, we found that less than 10% of children and adults under 70 years of age had seroprotective levels of antibody against the pandemic (H1N1) virus. 1 This proportion was slightly higher among people aged 70-79 years (27%) and substantially higher among those above 80 years of age (77%). 1 The 2009 influenza pandemic and the broad and effective vaccination campaign introduced major changes to this population's immune status. The first wave in the province, in the spring and summer months, was of limited activity and was followed by a second, more substantial and widespread wave in the fall that peaked during the last week of October and resolved by the end of 2009. 2 Meanwhile, a highly immunogenic adjuvanted vaccine was provided free of charge through a universal vaccination campaign that targeted all Canadians. 3 Supply was limited initially, requiring sequenced rollout of the vaccine, starting with children under five years of age, pregnant women, and people under 65 years who had comorbidities. 4 The uptake of the vaccine of about 35%-45% in the province overall [4] [5] [6] and 44% in the Lower Mainland (Dr. Monika Naus, BC Centre for Disease Control, Vancouver, BC: personal communication, 2010) was estimated to be moderate compared with rates of uptake in other provinces.
To assess seroprotective antibody levels after the 2009 pandemic, we repeated our age-based survey of antibody levels against the pandemic (H1N1) 2009 virus in a further 1000 serum samples collected from people in the Lower Mainland in May and June 2010, more than six months after the last peak of the epidemic.
Methods
Residual serum samples collected from patients who presented between May 8 and 21, 2010, were obtained from the central processing laboratory of a community laboratory net-DOI:10.1503/cmaj.100910
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Serum samples were collected at multiple community patient service centres across this region, with slight overrepresentation from municipalities of the Fraser Valley relative to the Vancouver metropolitan area. About 100 samples were assembled for each of the following age groups: < 5, 5-9, 10-19, 20-29, 30-39, 40-49, 50-59, 60-69, 70-79, 80-89 and ≥ 90 years. To enable finer stratification in pediatric age groups, additional samples were collected between June 15 and 17, 2010, from children less than two years (7) and two to four years of age (20) , which gave us totals of 26 and 100 serum samples in these two youngest age groups.
All of the samples were anonymized and provided without additional clinical detail (e.g., testing indication or vaccination history), such that individual consent was not required. The Clinical Research Ethics Board of the University of British Columbia approved the study.
The main outcome was the level of antibody against the pandemic (H1N1) 2009 virus, as measured by the hemagglutination inhibition assay and supplemented by the microneutralization assay. Both assays were performed at the BC Centre for Disease Control using a BC isolate of the influenza A/California/7/2009 virus per standard protocol (described in Appendix 1, available at www.cmaj.ca /cgi /content /full /cmaj .100910 /DC1). Titres were summarized at the individual level as the geometric mean of duplicate inverse titres, with titres of less than 10 assigned a value of five. As previously defined, seroprotection was noted if the hemagglutination inhibition titre was 40 or higher. 1, 8, 9 Geometric mean titres and the proportion of people with seroprotection, with Waldbased 95% confidence intervals, were summarized by age group. Sensitivity analyses included titre thresholds of 80, 20 and 10. Direct standardization with 2010 population projections for the Lower Mainland region of the province generated an estimate of the overall age-standardized proportion of people who had seroprotection.
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Results
Serum samples collected from 1127 people (aged 9 months to 101 years) were included in our study ( Figure 1 ). Whereas seroprotection was high among people less than 20 years of age (70%, 95% CI 65%-75%), it was significantly lower among adults 20-49 years (44%, 95% CI 39%-50%) and lower still among those 50-79 years (30%, 95% CI 25%- The sensitivity analyses showed similar U-shaped distributions by age in the proportion of people meeting or exceeding titre thresholds of 80, 20 or 10 (Appendix 2, available at www.cmaj.ca /cgi /content /full/cmaj.100910/DC1). Among the age groups with the lowest levels of seroprotection, the proportion with hemagglutination inhibition titres of 10 or higher was 57% of those aged 50-59 years, 71% of those 60-69 years and 69% of those 70-79 years. The corresponding proportions with microneutralization titres of 10 or higher were 71%, 82% and 66% in these three age groups. However, these findings represented mostly low-level antibody detection, because the proportion of people with titres of 20 or higher was lower in the same age groups (hemagglutination assay: 40% of those aged 50-59 years, 50% of those 60-69 years and 42% of those 70-79; microneutralization assay: 43% of those aged 50-59 years, 50% of those 60-69 years and 26% of those 70-79). As in the primary analysis, the proportion of people with titres of at least 80 was highest among those less than 20 years old and among those 90 years of age and older; it was lowest among those 50-79 years old. The overall agestandardized proportion with a titre of at least 80 was 25% (95% CI 22%-28%) by hemagglutination inhibition assay and 29% (95% CI 26%-32%) by microneutralization assay.
Interpretation
In this follow-up study, conducted more than six months after the fall 2009 pandemic and vaccination campaign, we found a different U-shaped distribution of seroprotection by age group compared with our findings in the same region before these events. 1 The substantial increase in seroprotection we ob served in the young groups may have resulted from higher attack rates of pandemic (H1N1) influenza 4,10-14 and earlier prioritization of vaccination among young children. 4, 6 In the Lower Mainland region of British Columbia, a telephone survey showed that the profile of pandemic (H1N1) vaccine coverage by age also followed a U-shaped distribution, being highest among children less than 10 years old and people 65 years and older (57% in each group), but lower among school-aged children 10-19 years old (37%), adults 20-49 years old (38%) and adults 50-64 years old (47%) (Dr. Monika Naus: personal communication, 2010). Rates of pandemic (H1N1) influenza were reported to have been highest among school-aged children, 4,10-14 which likely contributed to higher seroprotection despite lower vaccine coverage among those 10-19 years old.
The people who had the lowest rate of seroprotection (titre ≥ 40) after the 2009 pandemic were those 50-79 years old. Of note, the levels of seroprotection among those 70-79 did not change measurably after the pandemic (hemagglutination inhibition assay: 27% before and 21% after the pandemic; microneutralization assay: 6% before and 13% after the pandemic).
1 These low levels after the pandemic, despite substantial vaccine coverage (about 60%) in this age group, warrant further investigation because it may signal aberrant responses to the vaccine. People 70-79 years of age were reported to have had the lowest seropositivity rate in a similar serologic survey conducted in mid-November and early December 2009 among residents in Pittsburgh, Pennsylvania. 14 A discrepancy between estimates of post pandemic seroprotection and adjuvanted pandemic (H1N1) vaccine coverage among adults aged 50-79 years was also noted in at least one other serologic survey in Norway. 15 At a population level, the critical fraction of immunity required to prevent sustained transmission is related to a pathogen's reproductive number (R o ), expressed as 1 -1/R o . Lower estimates of R o imply lower levels of immunity required to prevent an epidemic. Various estimates of R o have been derived for the pandemic (H1N1) virus, ranging up to 3.0 in the setting of a school outbreak, but are generally between 1.5 and 2.0 on average. [16] [17] [18] [19] [20] On that basis, community-level protection against the pandemic (H1N1) virus in the range of 33%-50% overall would be enough to prevent an epidemic, assuming random mixing of people of different ages and homogeneous immunity. School-aged children, however, are thought to contribute disproportionately to influenza transmission. 21 Our study identified seroprotection estimates of 46% overall by hemagglutination inhibition assay (41% by microneutralization assay) and 70% (64% by microneutralization assay) among schoolaged children.
In combination, these findings reassure against the likelihood of a substantial third wave of pandemic (H1N1) during the 2010/11 influenza season, unless there is substantial waning of antibody levels or a change in the virus. Such drift has not occurred to date in the dominant circulating pandemic (H1N1) strain but may be considered a future likelihood. Until then, sporadic cases or limited pockets of activity will likely occur, but the high attack rates of pandemic (H1N1) influenza observed in 2009, especially among children, now appear improbable in the Lower Mainland region of British Columbia for the coming season.
As in previous pandemics, surveillance reports of pandemic (H1N1) 2009 consistently showed that incidence rates were highest among young people, whereas the risk of death from the disease was highest among elderly people. 4, [22] [23] [24] [25] [26] [27] [28] [29] A high incidence of infection among young people, multiplied by even a small likelihood of death, can still result in more pediatric deaths, as evident in the 2009 pandemic. A shift in the age distribution back toward a more typical seasonal pattern of disproportionate burden of severe disease in older groups has generally taken several years to occur following other pandemics. 22 In the absence of vaccination, this shift occurs gradually as young people accumulate infectioninduced immunity over successive epidemics and their influenza attack rates diminish. The results of our study suggest that high levels of immunity against pandemic (H1N1) influenza among young people were achieved much more quickly -within a year of the 2009 pandemic. This rapid change occurred probably because a massive pandemic vaccination campaign with highly immunogenic adjuvanted vaccine supplemented the population immunity induced by the high pandemic attack rates. As a result, the high attack rates that contributed to severe outcomes among young people during the 2009 pandemic are unlikely to recur during the 2010/11 influenza season.
Conversely, adults aged 50-79 years had lower seroprotection against the pandemic virus while remaining at intrinsically higher risk of severe illness and death if infected. In that context, a shift in disease burden back toward older adults accounting for a greater proportion of severe outcomes may come about more rapidly than was observed with previous pandemics. A demographic shift in disease burden toward adults generally next season has been proposed in recent mathematical models from Canada and the United States. 30 For the coming 2010/11 influenza season, the World Health Organization has recommended that the pandemic (H1N1) virus be included in the seasonal trivalent influenza vaccine. More active targeting of this trivalent vaccine to people 50 years and older for the coming influenza season, particularly those with comorbidities, could provide protection against severe outcomes due not only to pandemic (H1N1) influenza but also to seasonal influenza.
Limitations
There are several caveats to the interpretation of our results. We dichotomized hemagglutination inhibition titres at 40 because this cut-off is the conventional 50% seroprotective threshold routinely applied to seasonal influenza and to vaccine approval. 8, 9 However, this threshold has not been validated specifically for the pandemic (H1N1) virus or all age groups. We measured higher proportions but the same Ushaped distribution by age group for antibody titres exceeding lower thresholds of 10 or 20. Lower thresholds are of uncertain clinical significance but may signal virus exposure contributing to other forms of protection (e.g., heterologous cellmediated immunity). In general, however, higher influenza antibody titres signal higher likelihood of protection, so that the similar age-related pattern observed at thresholds of 40 or 80 are likely to be more meaningful. 8, 9 For efficiency, we used convenience sampling of about 100 anonymized residual serum samples per 10-year age group collected from patients who presented for other clinical testing. We did not have additional details about their comorbidities or vaccination history. We cannot readily interpret age-related seroprotection more finely than the per decade sampling we conducted, and further evaluation of more discrete ages may be warranted. Also, convenience sampling may have led to an overestimate of seroprotection. Patients having blood drawn for a clinical indication may have a greater prevalence of underlying conditions or health care behaviours associated with a higher likelihood of receiving the pandemic (H1N1) vaccine. However, this influence on our findings was unlikely to be strong, because the estimated seroprotection was lowest among people aged 50-79 years, among whom chronic comorbidities become increasingly prevalent. Conversely, unmeasured comorbidities conferring immunosuppression could have resulted in underestimation of the true proportion considered to have seroprotection.
For comparative purposes, we restricted our study to the same region in which we had conducted our previous serologic survey. 1 However, different people in the region were included in each study, and thus seroconversion cannot be directly computed. Seroprotection may be lower in less densely populated areas where attack rates were lower or in places where a less immunogenic vaccine was used or where lower vaccine coverage was achieved. British Columbia reported moderate vaccine coverage overall, which suggests that levels of seroprotection may be even higher in provinces with greater vaccine coverage. 4−6 A vaccination registry did not exist in British Columbia to enable precise estimation of age-specific uptake of the pandemic (H1N1) vaccine. We were unable to assess directly the proportion of people whose seroprotection was attributed to infection rather than to vaccination. Nonetheless, it is reassuring that, in most age groups for which vaccination data were available, our estimates of seroprotection approximated or exceeded the measured vaccine coverage cited above. However, vaccine coverage in the Lower Mainland region was nearly 60% among people 65 years and older (Dr. Monika Naus: personal communication, 2010). As such, we would have expected to find a higher proportion of elderly people up to 79 years of age with seroprotective titres. Response to vaccine may vary by age, although clinical trials have shown that the adjuvanted vaccine used in Canada induced high antibody titres, exceeding typical seasonal vaccine responses, with seroprotection rates of more than 90% in all age groups assessed, including people over 60 years old. 3 We measured antibody levels more than six months after the vaccination campaign. Over that prolonged interval, estimates of seroprotection, although high in younger groups, may have waned from an earlier peak. Our estimates from samples collected in May and June 2010 may not absolutely reflect seroprotection for the upcoming 2010/11 influenza season, but age-related comparisons should be robust because the rate of decline of influenza antibody levels is not considered to be strongly influenced by age.
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Conclusion
Our estimates of seroprotection against pandemic (H1N1) influenza in the Lower Mainland of British Columbia were dramatically different from levels measured in the same region before the fall 2009 pandemic wave and vaccination campaign. These estimates likely preclude a third pandemic wave for the coming 2010/11 influenza season, unless there is substantial waning of immunity or a change in the virus. People 50-79 years old had low levels of seroprotection while remaining at higher risk of severe illness and death if infected. Our findings support a shift from prioritized vaccination of young people that occurred in fall 2009 to prioritized vaccination of older adults for the coming 2010/11 influenza season. Given the implications, our estimates of seroprotection should be assessed in other settings and closer to the influenza season.
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